• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy Treatment for Advanced Prostate Cancer
【24h】

Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy Treatment for Advanced Prostate Cancer

机译：II期免疫治疗试验：联合雄激素消融疗法治疗晚期前列腺癌

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objectives of this study are to test whether CTLA 4 blockade + AA therapy canenhance clinical treatment responses in advanced prostate cancer patients relative to AA therapy alone. Study patients are randomized to 3 months of combined AA therapy + MDX-010 or versus AA therapy alone. To date, 46 patients have been enrolled and 42 randomized per protocol. An additional 84 patients have been screened and deemed ineligible for study. 29 patients now have sufficient follow-up to assess if any treatment effects may be occurring. In general, patients receiving combined AA + MDX-010 have exhibited greater PSA responses than patients receiving AA therapy alone. We have also observed that MDX-010 does not likely affect initial testosterone production but may delay testosterone recovery. Our preliminary studies also indicate atypical and favorable responses to combined MDX-010 + AA therapy including reversal of rising PSA, rapid resolution of obstructive urinary pathology and dramatic tumor downstaging resulting in unexpected 1 year disease-free patient status. Based on these preliminary observations, we believe that combined AA + MDX-010 treatment may encompass a promising approach to improve advanced prostate cancer treatment.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号